Boston Scientific's Cash & cash equivalent grew by 20.69 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Boston Scientific's Quick Ratio to 0.13, Quick Ratio remained below Boston Scientific Corporation average.

Within Medical Equipment & Supplies industry 181 other companies have achieved higher Quick Ratio than Boston Scientific in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 3086, from total ranking in the second quarter 2026 at 3647.

Explain Quick Ratio?
How much Cash & cash equivalents BSX�s has?
What are BSX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BSX/financial-strength

https://api.csimarket.com/api/v1/companies/BSX/fundamentals

https://api.csimarket.com/api/v1/companies/BSX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

BSX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	34.2 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-29.1 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.13	Subscribe	Subscribe	Subscribe	Subscribe
BSX's Total Ranking	# 3086	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-5.05 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	20.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Equipment & Supplies Industry	# 182
Healthcare Sector	# 848
Overall Market	# 3682

Quick Ratio Statistics
High	Average	Low
0.82	0.31	0.03
(Sep. 30. 2004)		(Jun 30 2019)

Financial Statements
Boston Scientific's Current Liabilities	$ 7,150 Millions	Visit BSX's Balance sheet
Boston Scientific's Cash & cash equivalent	$ 904 Millions	Visit BSX's Balance sheet
Source of BSX's Sales		Visit BSX's Sales by Geography

Cumulative Boston Scientific's Quick Ratio

BSX's Quick Ratio for the trailling 12 Months

BSX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	12.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	72.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.21	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2641	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	7.97 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-6.82 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to BSX Financial Strength Comparisons >> Go to Compare BSX Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2026 to $7,150.00 millions, cumulative Quick Ratio decreased to 0.21 below the Boston Scientific Corporation average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 205 other companies have achieved higher Quick Ratio than Boston Scientific. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4086.

Explain Quick Ratio?
How much Cash & cash equivalents BSX�s has?
What are BSX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Equipment & Supplies Industry	# 206
Healthcare Sector	# 909
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.59	0.27	0.03
(March 31, 2007)		(Mar 31 2019)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Tela Bio Inc	0.31	$ 22.664 Millions	$ 73.706 Millions
Tandem Diabetes Care Inc	0.28	$ 72.840 Millions	$ 256.075 Millions
Ufp Technologies Inc	0.27	$ 20.625 Millions	$ 77.359 Millions
Docgo Inc	0.26	$ 20.569 Millions	$ 79.655 Millions
Bausch and Lomb Corp	0.25	$ 513.000 Millions	$ 2,019.000 Millions
Accuray Incorporated	0.25	$ 42.254 Millions	$ 170.106 Millions
Cerus Corporation	0.20	$ 16.350 Millions	$ 80.006 Millions
Bioventus Inc	0.19	$ 30.709 Millions	$ 159.282 Millions
Dentsply Sirona Inc	0.15	$ 195.000 Millions	$ 1,312.000 Millions
Boston Scientific Corporation	0.13	$ 904.000 Millions	$ 7,150.000 Millions
Solventum Corporation	0.13	$ 451.000 Millions	$ 3,575.000 Millions
The Pennant Group Inc	0.12	$ 18.389 Millions	$ 151.730 Millions
Zimmer Biomet Holdings Inc	0.11	$ 399.900 Millions	$ 3,502.400 Millions
Integer Holdings Corporation	0.07	$ 14.135 Millions	$ 201.125 Millions
3m Company	0.03	$ 322.000 Millions	$ 11,868.000 Millions

Date modified: 2026-11-03T09:56:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.